Base de dados : MEDLINE
Pesquisa : D03.633.100.079.080.070.565 [Categoria DeCS]
Referências encontradas : 761 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 77 ir para página                         

  1 / 761 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28606603
[Au] Autor:Konishi K; Fukami T; Gotoh S; Nakajima M
[Ad] Endereço:Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
[Ti] Título:Identification of enzymes responsible for nitrazepam metabolism and toxicity in human.
[So] Source:Biochem Pharmacol;140:150-160, 2017 Sep 15.
[Is] ISSN:1873-2968
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Nitrazepam (NZP) is a hypnotic agent that rarely causes liver injuries in humans and teratogenicity in rodents. In humans, NZP is primarily metabolized to 7-aminonitrazepam (ANZP) by reduction and subsequently to 7-acetylamino nitrazepam (AANZP) by acetylation. ANZP can be regenerated from AANZP by hydrolysis in rodents, but it is still unclear whether this reaction occurs in humans. In rodents, AANZP may be associated with teratogenicity, while in humans, it is known that drug-induced liver injuries may be caused by NZP reactive metabolite(s). In this study, we attempted to identify the enzymes responsible for NZP metabolism to obtain a basic understanding of this process and the associated metabolite toxicities. We found that the NZP reductase activity in human liver cytosol (HLC) was higher than that in human liver microsomes (HLM). We purified the responsible enzyme(s) from HLC and found that the NZP reductase was aldehyde oxidase 1 (AOX1). The role of AOX1 was confirmed by an observed increase in the NZP reductase activity upon addition of N -methylnicotinamide, an electron donor of AOX1, as well as inhibition of this activity in HLC in the presence of AOX1 inhibitors. ANZP was acetylated to form AANZP by N-acetyltransferase (NAT) 2. An experiment using recombinant esterases in an inhibition study using HLM revealed that AANZP is hydrolyzed by arylacetamide deacetylase (AADAC) in the human liver. N-Hydroxylamino NZP, which is suspected to be a reactive metabolite, was detected as a conjugate with N-acetyl-l-cysteine through NZP reduction and ANZP hydroxylation reactions. In the latter reaction, the conjugate was readily formed by recombinant CYP3A4 among the various P450 isoforms tested. In sum, we found that AOX1, NAT2, AADAC, and CYP3A4 are the determinants for the pharmacokinetics of NZP and that they confer interindividual variability in sensitivity to NZP side effects.
[Mh] Termos MeSH primário: Aldeído Oxidase/metabolismo
Arilamina N-Acetiltransferase/metabolismo
Hidrolases de Éster Carboxílico/metabolismo
Citocromo P-450 CYP3A/metabolismo
Hepatócitos/metabolismo
Hipnóticos e Sedativos/metabolismo
Nitrazepam/metabolismo
[Mh] Termos MeSH secundário: Acetilação
Aldeído Oxidase/antagonistas & inibidores
Aldeído Oxidase/química
Aldeído Oxidase/isolamento & purificação
Arilamina N-Acetiltransferase/genética
Biotransformação
Hidrolases de Éster Carboxílico/genética
Citocromo P-450 CYP3A/genética
Citosol/enzimologia
Citosol/metabolismo
Inibidores Enzimáticos/farmacologia
Hepatócitos/enzimologia
Seres Humanos
Hidrólise/efeitos dos fármacos
Hidroxilação
Hipnóticos e Sedativos/efeitos adversos
Cinética
Microssomos Hepáticos/enzimologia
Microssomos Hepáticos/metabolismo
Nitrazepam/efeitos adversos
Nitrazepam/análogos & derivados
Oxirredução
Proteínas Recombinantes/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Enzyme Inhibitors); 0 (Hypnotics and Sedatives); 0 (Recombinant Proteins); 1A49O337AZ (7-aminonitrazepam); 4928-03-4 (7-acetamidonitrazepam); 9CLV70W7HS (Nitrazepam); EC 1.14.13.67 (CYP3A4 protein, human); EC 1.14.14.1 (Cytochrome P-450 CYP3A); EC 1.2.3.1 (AOX1 protein, human); EC 1.2.3.1 (Aldehyde Oxidase); EC 2.3.1.5 (Arylamine N-Acetyltransferase); EC 2.3.1.5 (NAT2 protein, human); EC 3.1.1.- (AADAC protein, human); EC 3.1.1.- (Carboxylic Ester Hydrolases)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170818
[Lr] Data última revisão:
170818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170614
[St] Status:MEDLINE


  2 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28039836
[Au] Autor:Xi JB; Fang YF; Frett B; Zhu ML; Zhu T; Kong YN; Guan FJ; Zhao Y; Zhang XW; Li HY; Ma ML; Hu W
[Ad] Endereço:Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
[Ti] Título:Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.
[So] Source:Eur J Med Chem;126:1083-1106, 2017 Jan 27.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:We present herein the discovery and development of novel and potent Nek2 inhibitors with distinctive in vitro and in vivo antitumor activity based on an imidazo[1,2-a]pyridine scaffold. Our studies identified a nonlinear SAR for activity against both Nek2 and cancer cells. Bioisostere and structure-based design techniques were employed to identify compounds 42c (MBM-17, IC = 3.0 nM) and 42g (MBM-55, IC = 1.0 nM), which displayed low nanomolar activity and excellent selectivity for Nek2. Both compounds effectively inhibited the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. Importantly, the salts form of these two compounds (MBM-17S and MBM-55S) significantly suppressed tumor growth in vivo without apparent toxicity based on appearance and changes in body weight. In summary, MBM-17 and MBM-55 displayed the potential for substantial therapeutic application in cancer treatment.
[Mh] Termos MeSH primário: Desenho de Drogas
Quinases Relacionadas a NIMA/antagonistas & inibidores
Nitrazepam/química
Piridinas/síntese química
Piridinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/síntese química
Antineoplásicos/química
Antineoplásicos/farmacocinética
Antineoplásicos/farmacologia
Apoptose/efeitos dos fármacos
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Técnicas de Química Sintética
Relação Dose-Resposta a Droga
Ensaios de Seleção de Medicamentos Antitumorais
Feminino
Pontos de Checagem da Fase G2 do Ciclo Celular/efeitos dos fármacos
Seres Humanos
Pontos de Checagem da Fase M do Ciclo Celular/efeitos dos fármacos
Masculino
Camundongos
Simulação de Acoplamento Molecular
Quinases Relacionadas a NIMA/química
Quinases Relacionadas a NIMA/metabolismo
Poliploidia
Conformação Proteica
Inibidores de Proteínas Quinases/síntese química
Inibidores de Proteínas Quinases/química
Inibidores de Proteínas Quinases/farmacocinética
Inibidores de Proteínas Quinases/farmacologia
Piridinas/química
Piridinas/farmacocinética
Ratos
Relação Estrutura-Atividade
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Protein Kinase Inhibitors); 0 (Pyridines); 9CLV70W7HS (Nitrazepam); EC 2.7.11.1 (NEK2 protein, human); EC 2.7.11.1 (NIMA-Related Kinases)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170222
[Lr] Data última revisão:
170222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170101
[St] Status:MEDLINE


  3 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27615446
[Au] Autor:Nikoui V; Ostadhadi S; Azhand P; Zolfaghari S; Amiri S; Foroohandeh M; Motevalian M; Sharifi AM; Bakhtiarian A
[Ad] Endereço:School of Pharmacy, International Campus, Tehran University of Medical Sciences, Tehran, Iran; Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
[Ti] Título:The effect of nitrazepam on depression and curiosity in behavioral tests in mice: The role of potassium channels.
[So] Source:Eur J Pharmacol;791:369-376, 2016 Nov 15.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Evidence show that gamma-aminobutyric acid (GABA) receptors are involved in depression, so the aim of this study was to investigate the effect of nitrazepam as agonist of GABA receptors on depression and curiosity in male mice and the role of potassium channel in antidepressant-like response. For this purpose, we studied the antidepressant-like properties of fluoxetine, nitrazepam, glibenclamide, and cromakalim by both forced swimming test (FST) and tail suspension test (TST). Animals were injected by various doses of nitrazepam (0.05, 0.1, and 0.5mg/kg). Nitrazepam at dose of 0.5mg/kg significantly decreased the immobility time compared to control group in both FST and TST. Fluoxetine also showed such a response. Co-administration of nitrazepam (0.05mg/kg) with glibenclamide in TST (1mg/kg) and in FST (0.3, 1mg/kg) also showed antidepressant-like response. Beside, cromakalim (0.1mg/kg) could reverse the antidepressant-like effect of nitrazepam (0.5mg/kg) in both FST and TST, while cromakalim and glibenclamide alone could not change the immobility time compared to control group (P>0.05). The hole-board test revealed that nitrazepam at doses of 0.5 and 0.1mg/kg could increase the activity of the animal's head-dipping and boost the curiosity and exploration behavior of mice. The results of this study revealed that nitrazepam may possess antidepressant-like properties and this effect is dependent to potassium channels in both FST and TST.
[Mh] Termos MeSH primário: Antidepressivos/farmacologia
Comportamento Animal/efeitos dos fármacos
Depressão/tratamento farmacológico
Depressão/metabolismo
Comportamento Exploratório/efeitos dos fármacos
Nitrazepam/farmacologia
Canais de Potássio/metabolismo
[Mh] Termos MeSH secundário: Animais
Antidepressivos/uso terapêutico
Cromakalim/farmacologia
Depressão/psicologia
Glibureto/farmacologia
Masculino
Camundongos
Nitrazepam/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Potassium Channels); 0G4X367WA3 (Cromakalim); 9CLV70W7HS (Nitrazepam); SX6K58TVWC (Glyburide)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160913
[St] Status:MEDLINE


  4 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27013620
[Au] Autor:Vindenes V; Strand DH; Koksæter P; Gjerde H
[Ad] Endereço:Division of Forensic Sciences, Norwegian Institute of Public Health, PO Box 4404 Nydalen, NO-0403 Oslo, Norway Norwegian Centre for Addiction Research (SERAF), University of Oslo, PO Box 1039, Blindern, NO-0315 Oslo, Norway vigdis.vindenes@fhi.no.
[Ti] Título:Detection of Nitrobenzodiazepines and Their 7-Amino Metabolites in Oral Fluid.
[So] Source:J Anal Toxicol;40(4):310-2, 2016 May.
[Is] ISSN:1945-2403
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Clonazepam, nitrazepam and flunitrazepam are frequently used benzodiazepines, both as prescribed medication and as drugs of abuse. Little is, however, known about how these drugs are excreted in oral fluid. It has been claimed that the parent drugs are more likely to be detected in oral fluid than the 7-amino metabolites. The aim of this study was to investigate whether the parent drugs or the 7-amino metabolites of the nitrobenzodiazepines were most frequently detected in authentic oral fluid samples. Oral fluid samples were collected from patients undergoing opioid maintenance treatment. Cases where clonazepam, nitrazepam, flunitrazepam and/or their metabolites were detected were included. The samples were collected using the Intercept Oral Specimen Collection Device. A cutoff concentration of 1 nM (∼0.3 ng/mL) in oral fluid-buffer mixture was applied for all the substances. A total of 1,001 oral fluid samples were positive for clonazepam and/or 7-aminoclonazepam; both substances were detected in 707 samples, only the parent drug in 64 cases and only the metabolite in 230 cases. For nitrazepam, both substances were detected in 139 samples; only the parent drug in 16 cases and only the metabolite in 56 cases. Flunitrazepam only was not detected in any sample; both substances were detected in one of these cases, and only the metabolite in three cases. This study revealed that 7-amino metabolites were more likely to be detected in oral fluid than the parent drugs.
[Mh] Termos MeSH primário: Benzodiazepinas/análise
Saliva/química
[Mh] Termos MeSH secundário: Benzodiazepinas/metabolismo
Clonazepam/análogos & derivados
Clonazepam/análise
Flunitrazepam/análise
Seres Humanos
Nitrazepam/análise
Tratamento de Substituição de Opiáceos
Detecção do Abuso de Substâncias/métodos
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
12794-10-4 (Benzodiazepines); 17D6640Q7Y (7-aminoclonazepam); 5PE9FDE8GB (Clonazepam); 620X0222FQ (Flunitrazepam); 9CLV70W7HS (Nitrazepam)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170119
[Lr] Data última revisão:
170119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160326
[St] Status:MEDLINE
[do] DOI:10.1093/jat/bkw020


  5 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26285109
[Au] Autor:Allsop DJ; Bartlett DJ; Johnston J; Helliwell D; Winstock A; McGregor IS; Lintzeris N
[Ad] Endereço:School of Psychology, University of Sydney, Sydney, NSW, Australia.
[Ti] Título:The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence.
[So] Source:J Clin Sleep Med;11(10):1153-62, 2015 Oct 15.
[Is] ISSN:1550-9397
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:STUDY OBJECTIVE: Sleep disturbance is a hallmark feature of cannabis withdrawal. In this study we explored the effects of lithium treatment supplemented with nitrazepam on objective and subjective measures of sleep quality during inpatient cannabis withdrawal. METHODS: Treatment-seeking cannabis-dependent adults (n = 38) were admitted for 8 days to an inpatient withdrawal unit and randomized to either oral lithium (500 mg) or placebo, twice daily in a double-blind RCT. Restricted nitrazepam (10 mg) was available on demand (in response to poor sleep) on any 3 of the 7 nights. Dependent outcome measures for analysis included repeated daily objective actigraphy and subjective sleep measures throughout the 8 day detox, subjective cannabis withdrawal ratings, and detoxification completion rates. RESULTS: Based on actigraphy, lithium resulted in less fragmented sleep compared to placebo (p = 0.04), but no other objective measures were improved by lithium. Of the subjective measures, only nightmares were suppressed by lithium (p = 0.04). Lithium did not have a significant impact on the use of nitrazepam. Sleep bout length (p < 0.0001), sleep efficiency (p < 0.0001), and sleep fragmentation (p = 0.05) were improved on nights in which nitrazepam was used. In contrast, only night sweats improved with nitrazepam from the subjective measures (p = 0.04). A Cox regression with daily repeated measures of sleep efficiency averaged across all people in the study a predictor suggests that a one-unit increase in sleep efficiency (the ratio of total sleep time to the total time in bed expressed as a percentage) resulted in a 14.6% increase in retention in treatment (p = 0.008, Exp(B) = 0.854, 95% CI = 0.759-0.960). None of the other sleep measures, nor use of lithium or nitrazepam were significantly associated with retention in treatment. CONCLUSIONS: Lithium seems to have only limited efficacy on sleep disturbance in cannabis withdrawal. However the nitrazepam improved several actigraphy measures of sleep disturbance, warranting further investigation. Discord between objective and subjective sleep indices suggest caution in evaluating treatment interventions with self-report sleep data only.
[Mh] Termos MeSH primário: Cannabis/efeitos adversos
Carbonato de Lítio/farmacologia
Nitrazepam/farmacologia
Distúrbios do Início e da Manutenção do Sono/induzido quimicamente
Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico
Síndrome de Abstinência a Substâncias/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Inibidores Enzimáticos/farmacologia
Feminino
Seres Humanos
Hipnóticos e Sedativos/farmacologia
Masculino
Sono/efeitos dos fármacos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Enzyme Inhibitors); 0 (Hypnotics and Sedatives); 2BMD2GNA4V (Lithium Carbonate); 9CLV70W7HS (Nitrazepam)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160415
[Lr] Data última revisão:
160415
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150819
[St] Status:MEDLINE
[do] DOI:10.5664/jcsm.5090


  6 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25755221
[Au] Autor:Goudarzi N; Farsimadan S; Chamjangali MA; Bagherian GA
[Ad] Endereço:Faculty of chemistry, University of Shahrood, Shahrood, Iran.
[Ti] Título:Optimization of modified dispersive liquid-liquid microextraction coupled with high-performance liquid chromatography for the simultaneous preconcentration and determination of nitrazepam and midazolam drugs: An experimental design.
[So] Source:J Sep Sci;38(10):1673-9, 2015 May.
[Is] ISSN:1615-9314
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:A simple, sensitive, and rapid microextraction method, namely, ultrasound-assisted surfactant-enhanced emulsification microextraction based on the solidification of floating organic droplet method coupled with high-performance liquid chromatography was developed for the simultaneous preconcentration and determination of nitrazepam and midazolam. The significant parameters affecting the extraction efficiency were considered using Plackett-Burman design as a screening method. To obtain the optimum conditions with consideration of the selected significant variables, a Box-Behnken design was used. The microextraction procedure was performed using 29.1 µL of 1-undecanol, 1.36% (w/v) of NaCl, 10.0 µL of sodium dodecyl sulfate (25.0 µg mL(-1)), and 1.0 µL of Tween80 (25.0 µg mL(-1)) as an emulsifier in an extraction time of 20.0 min at pH 7.88. In order to investigate the validation of the developed method, some validation parameters including the linear dynamic range, repeatability, limit of detection, and recoveries were studied under the optimum conditions. The detection limits of the method were 0.017 and 0.086 ng mL(-1) for nitrazepam and midazolam, respectively. The extraction recovery percentages for the drugs studied were above 91.0 with acceptable relative standard deviation. The proposed methodology was successfully applied for the determination of these drugs in a number of human serum samples.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Hipnóticos e Sedativos/sangue
Microextração em Fase Líquida/métodos
Midazolam/sangue
Nitrazepam/sangue
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 9CLV70W7HS (Nitrazepam); R60L0SM5BC (Midazolam)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150527
[Lr] Data última revisão:
150527
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150311
[St] Status:MEDLINE
[do] DOI:10.1002/jssc.201500007


  7 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25674736
[Au] Autor:Iqbal U; Nguyen PA; Syed-Abdul S; Yang HC; Huang CW; Jian WS; Hsu MH; Yen Y; Li YC
[Ad] Endereço:From the Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan (UI, P-AN, SS-A, H-CY, CWH, M-HH, YY, YC(J)L); Institute of Biomedical Informatics, National Yang Ming University, Taipei, Taiwan (H-CY); School of Health Care Administration, Taipei Medical University, Taipei, Taiwan (W-SJ); Department of Health, Taipei Hospital, Taiwan (M-HH); City of Hope, Duarte, CA, USA (YY); Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan (Y-C(J)L).
[Ti] Título:Is long-term use of benzodiazepine a risk for cancer?
[So] Source:Medicine (Baltimore);94(6):e483, 2015 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The carcinogenicity of benzodiazepines (BZDs) is still unclear. We aimed to assess whether long-term benzodiazepines use is risk for cancer.We conducted a longitudinal population-based case-control study by using 12 years from Taiwan National Health Insurance database and investigated the association between BZDs use and cancer risk of people aged over 20 years. During the study period, 42,500 cases diagnosed with cancer were identified and analyzed for BZDs use. For each case, six eligible controls matched for age, sex, and the index date (ie, free of any cancer in the date of case diagnosis) by using propensity score. For appropriate risk estimation, we observed the outcomes according to their length of exposure (LOE) and defined daily dose (DDD). To mimic bias, we adjusted with potential confounding factors such as medications and comorbid diseases which could influence for cancer risk during the study period. The data was analyzed by using Cox proportional hazard regression and conditional logistic regression.The finding unveils benzodiazepines use into safe and unsafe groups for their carcinogenicity. The use of diazepam (HR, 0.96; 95%CI, 0.92-1.00), chlorodizepoxide (HR, 0.98; 95%CI, 0.92-1.04), medazepam (HR, 1.01; 95%CI, 0.84-1.21), nitrazepam (HR, 1.06; 95%CI, 0.98-1.14), oxazepam (HR, 1.05; 95%CI, 0.94-1.17) found safer among BZDs. However, clonazepam (HR, 1.15; 95%CI, 1.09-1.22) were associated with a higher risk for cancers. Moreover, specific cancer risk among BZDs use was observed significantly increased 98% for brain, 25% for colorectal, and 10% for lung, as compared with non-BZDs use.Diazepam, chlordiazepoxide, medazepam, nitrazepam, and oxazepam are safe among BZDs use for cancer risk. Our findings could help physicians to select safer BZDs and provide an evidence on the carcinogenic effect of benzodiazepines use by considering the LOE and DDD for further research.
[Mh] Termos MeSH primário: Benzodiazepinas/efeitos adversos
Carcinógenos
[Mh] Termos MeSH secundário: Benzodiazepinas/administração & dosagem
Estudos de Casos e Controles
Clordiazepóxido/efeitos adversos
Clonazepam/efeitos adversos
Diazepam/efeitos adversos
Feminino
Seres Humanos
Modelos Logísticos
Estudos Longitudinais
Masculino
Medazepam/efeitos adversos
Meia-Idade
Nitrazepam/efeitos adversos
Oxazepam/efeitos adversos
Modelos de Riscos Proporcionais
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Carcinogens); 12794-10-4 (Benzodiazepines); 5PE9FDE8GB (Clonazepam); 6GOW6DWN2A (Oxazepam); 6RZ6XEZ3CR (Chlordiazepoxide); 9CLV70W7HS (Nitrazepam); P0J3387W3S (Medazepam); Q3JTX2Q7TU (Diazepam)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:150213
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000000483


  8 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24724359
[Au] Autor:Torikoshi A; Namera A; Arima Y; Toubou H; Tajima T; Shiraishi H; Nagao M
[Ti] Título:[Cross-reactivity of Instant-View M-1 for detection of benzodiazepine-related drugs and their metabolites in urine].
[So] Source:Chudoku Kenkyu;27(1):33-8, 2014 Mar.
[Is] ISSN:0914-3777
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Immunoassays are useful methods for the determination of regulated drugs in clinical and forensic laboratories. Although the Instant-View M-1 (IV M-1) immunoassay kit is frequently used to screen drugs in laboratories in Japan, basic information about the IV M-1 such as its specificity and reactivity is not available. In this study, we determined the specificity and cross-reactivity of IV M-1 for the detection of benzodiazepine-related drugs and their metabolites in urine. The IV M-1 could detect triazolobenzodiazepines such as triazolam in urine at concentrations > or = 300 ng/mL. However, thienodiazepines such as etizolam could not be detected because of lack of cross reactivity. A correlation was observed between the structure of the metabolites and the reactivity of the kit; 4-hydroxy metabolites of alprazolam and triazolam were detectable, whereas a-hydroxy metabolites were not. Furthermore, 7-amino metabolites such as nitrazepam could not be detected at any concentration, including high concentrations. The specificity and reactivity of various kits used for detection of drugs in urine are different. Therefore, it is necessary to consider the basic features of the kit used while assessing the results obtained.
[Mh] Termos MeSH primário: Benzodiazepinas/urina
Imunoensaio/métodos
Kit de Reagentes para Diagnóstico
Detecção do Abuso de Substâncias/métodos
[Mh] Termos MeSH secundário: Alprazolam/urina
Benzodiazepinas/química
Biomarcadores/urina
Reações Cruzadas
Diazepam/análogos & derivados
Seres Humanos
Nitrazepam
Sensibilidade e Especificidade
Relação Estrutura-Atividade
Triazolam/urina
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Reagent Kits, Diagnostic); 12794-10-4 (Benzodiazepines); 1HM943223R (Triazolam); 9CLV70W7HS (Nitrazepam); A76XI0HL37 (etizolam); Q3JTX2Q7TU (Diazepam); YU55MQ3IZY (Alprazolam)
[Em] Mês de entrada:1405
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140415
[St] Status:MEDLINE


  9 / 761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24717660
[Au] Autor:Han S; Li X; Wei B
[Ad] Endereço:School of Chemistry and Material Science, Shanxi Normal University.
[Ti] Título:Silver nanoparticle enhanced chemiluminescence method for the determination of nitrazepam.
[So] Source:Anal Sci;30(4):495-500, 2014.
[Is] ISSN:1348-2246
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:We report on a simple and sensitive chemiluminescence (CL) method to determine nitrazepam. This method is based on the fact that rhodamine 6G (Rh6G) enhanced the weak CL emission of the reaction of hexacyanoferrate with nitrazepam, and that it was further enhanced by silver nanoparticles (AgNPs). The effects of the concentrations of K3Fe(CN)6, Rh6G, AgNPs and NaOH on the CL reaction were investigated. Under the optimum conditions, the CL intensity was proportional to the concentration of nitrazepam in the range from 1.0 nM to 10.0 µM. The detection limit (3σ) was at 0.1 nM. The relative standard deviation was 2.1% (at a 0.1 µM concentration and for n = 11). The method was successfully applied to the determination of nitrazepam in Coca-Cola beverage, urine and plasma, and the recovery was 98 - 103%. We also considered the possible CL reaction mechanism.
[Mh] Termos MeSH primário: Medições Luminescentes/métodos
Nanopartículas Metálicas/química
Nitrazepam/análise
Prata/química
Detecção do Abuso de Substâncias/métodos
[Mh] Termos MeSH secundário: Ferricianetos/química
Corantes Fluorescentes/química
Seres Humanos
Limite de Detecção
Medições Luminescentes/instrumentação
Nitrazepam/sangue
Nitrazepam/urina
Rodaminas/química
Detecção do Abuso de Substâncias/instrumentação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Ferricyanides); 0 (Fluorescent Dyes); 0 (Rhodamines); 037VRW83CF (rhodamine 6G); 3M4G523W1G (Silver); 9CLV70W7HS (Nitrazepam)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140411
[St] Status:MEDLINE


  10 / 761 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24071944
[Au] Autor:Peng C; Duan X; Song S; Xue F
[Ad] Endereço:State Key Lab of Food Science and Technology, School of Food Science and Technology, Jiangnan University, Wuxi 214122, China. pcf@jiangnan.edu.cn.
[Ti] Título:Parts per trillion detection of 7-aminonitrazepam by nano-enhanced ELISA.
[So] Source:Int J Mol Sci;14(10):19474-83, 2013 Sep 25.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:It is challenging to detect 7-aminonitrazepam (7-ANZP) residue in animal tissues simply and sensitively by the enzyme-linked sorbent immunoassay (ELISA) method. This paper demonstrates that utilizing a bioconjugate of gold nanoparticles and enzyme-labeled antibody as a signal probe increases the sensitivity of a traditional ELISA for 7-ANZP by nearly 20 times. The sensitivity of this ELISA for 7-ANZP was 5.6 pg/mL in buffer, and the limit of detection (LOD) of 0.18 µg/kg for 7-ANZP in urine could be achieved after the urine samples were simply hydrolyzed and diluted by buffer. This simple and sensitive method has potential application for improving the sensitivity of ELISA methods against various small molecules.
[Mh] Termos MeSH primário: Ensaio de Imunoadsorção Enzimática/métodos
Nanopartículas/química
Nitrazepam/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Ouro/química
Imunoconjugados/química
Imunoglobulina G/química
Limite de Detecção
Nitrazepam/química
Proteínas/química
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Immunoconjugates); 0 (Immunoglobulin G); 0 (Proteins); 1A49O337AZ (7-aminonitrazepam); 7440-57-5 (Gold); 9CLV70W7HS (Nitrazepam)
[Em] Mês de entrada:1404
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130928
[St] Status:MEDLINE
[do] DOI:10.3390/ijms141019474



página 1 de 77 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde